Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera, Inc. (NASDAQ: NTRA) is a diagnostic and research company in the medical laboratories industry, focused on cell-free DNA testing and precision medicine in oncology, women’s health, and organ health. The Natera news feed on Stock Titan highlights company announcements, clinical data readouts, collaborations, and financial updates that reflect how its testing platforms are used in practice and research.
Recent news has featured advances in molecular residual disease (MRD) testing with Signatera, including new multi-modal AI models that integrate longitudinal circulating tumor DNA, clinical data, digital pathology, and tumor sequencing to refine recurrence risk assessment and outcomes prediction. Natera also reports on large clinical studies and trial analyses in colorectal cancer and breast cancer, where Signatera is used to evaluate MRD, predict treatment response, and support risk stratification.
In women’s health, news items include the launch and validation of Fetal Focus, a single-gene non-invasive prenatal test that uses cell-free DNA from maternal blood to assess inherited conditions when partner testing is not available, as well as updates related to the broader prenatal and carrier screening portfolio. Organ health news may cover the use of Natera’s Prospera test in transplant rejection assessment and related research.
Investors and clinicians can also follow Natera’s announcements about AI collaborations, such as its work with NVIDIA to scale multimodal AI foundation models, and corporate updates including preliminary financial results and participation in healthcare conferences. For those tracking NTRA, this news page provides a centralized view of developments across oncology, women’s health, organ health, and AI-enabled diagnostics.
Natera (NASDAQ: NTRA) reported strong Q3 2020 results with total revenues of $98.1 million, a 26% increase from Q3 2019, driven by a 39.5% rise in product revenues. The company processed 262,000 tests, up 31% year-over-year. Gross profit reached $46.3 million with a 47% gross margin. However, operating expenses grew to $102.1 million, leading to a net loss of $58.3 million, or ($0.72) per share. Natera raised its 2020 revenue guidance, expecting $380 million to $390 million in total revenues.
Natera, a leader in cell-free DNA testing, welcomes the ISPD's position statement endorsing cfDNA screening for twin pregnancies. This backing reinforces the clinical value of Non-Invasive Prenatal Testing (NIPT) for identifying autosomal trisomies. The statement emphasizes the importance of incorporating zygosity in NIPT interpretation, highlighting Natera's Panorama test's unique capability to assess zygosity and fetal fractions. This endorsement positions Natera favorably to expand its market leadership in NIPT.
Natera, a leader in cell-free DNA testing, is set to release its third quarter 2020 financial results on November 5, 2020, after market close. The company will hold a conference call at 1:30 PM PT to discuss these results, along with business activities and future outlook. Interested parties can join via live dial-in or webcast. Natera aims to transform disease management in women's health, oncology, and organ health, leveraging its innovative genetic testing services and cloud-based platform.
Natera, Inc. (NASDAQ: NTRA) announces the extension of non-invasive prenatal testing (NIPT) coverage for all singleton pregnancies by a major health plan, adding 17 million covered lives. This extends the total to 139 million commercial lives, representing approximately 77% of total lives covered for average risk NIPT in the U.S. This expansion aligns with new ACOG guidelines supporting NIPT, aiming to unlock volume growth in a currently underpenetrated market. Natera emphasizes its Panorama® test's advanced SNP-based technology and its extensive clinical evidence to support this growth.
Natera, Inc. (NASDAQ: NTRA) announced it will present new data at the 2020 American Society of Nephrology (ASN) Kidney Week virtual meeting from October 22-25. The presentations will focus on the Prospera test, demonstrating its efficacy in patients with second kidney transplants and those affected by COVID-19 or other viral infections. Key findings indicate significant differences in donor-derived cell-free DNA (dd-cfDNA) levels between rejection and non-rejection cases. These insights aim to enhance understanding of kidney transplant rejection across patient demographics.
Natera, Inc. (NASDAQ: NTRA) announced that Centene has extended coverage for its Panorama non-invasive prenatal test (NIPT) to all pregnant women, including those with twins, impacting 24 million additional covered lives. The extension follows ACOG and SMFM's new guidelines supporting NIPT for all patients, regardless of age or risk. Natera's General Manager highlighted the significant growth potential in the under-penetrated average risk NIPT market due to expanded insurance coverage. Panorama is the only NIPT that differentiates between maternal and fetal DNA, analyzing risks for genetic disorders as early as nine weeks into pregnancy.
Natera, a leader in cell-free DNA testing, has partnered with the George Lopez Foundation for the #GLFTrickShot Challenge, a social media campaign aimed at raising awareness and funds for kidney patients. The initiative encourages participants to post videos of themselves making trick shots, linking them to a fundraising page for donations. The campaign addresses the concerning statistic that approximately 96% of individuals with early-stage kidney disease are unaware of their condition. Prominent celebrities are participating, highlighting the campaign's reach and impact.
Natera, Inc. (NASDAQ: NTRA) announced a significant legal victory as the U.S. District Court of Delaware dismissed all challenges from ArcherDX regarding Natera's patent infringement case. The court upheld the validity of Natera's patents related to cancer monitoring, affirming their eligibility under U.S. patent law. Natera continues to pursue its five-patent infringement lawsuit against ArcherDX, emphasizing its commitment to protecting its technology and intellectual property in oncology. With over 200 patents, Natera aims to advance cell-free DNA testing and enhance disease management globally.
Natera, a leader in cell-free DNA testing, announced that its Signatera test will be utilized in the DARE study, a Phase II clinical trial evaluating palbociclib (IBRANCE®) for treating early-stage HR-positive, HER2-negative breast cancer. The trial aims to enroll approximately 100 MRD-positive patients to assess the efficacy of palbociclib in second-line adjuvant therapy. Signatera will monitor patient eligibility and treatment effectiveness. This collaboration with Yale and Criterium/ABRCC highlights the potential of personalized MRD testing in improving cancer management.
Natera, Inc. (NASDAQ: NTRA) has received a draft local coverage determination (LCD) from CMS’s Molecular Diagnostics Program for expanded coverage of its Signatera circulating tumor DNA (ctDNA) test, which monitors minimal residual disease (MRD) in cancer patients. The LCD allows for coverage of Signatera in various solid tumors and builds on Medicare's recent colorectal cancer coverage decision. The Signatera test boasts a 100% positive predictive value for identifying treatment non-responders and can detect residual disease up to 2 years earlier than standard methods.